Bartosz Pula1, Christopher Kobierzycki2, Daniel Solinski2, Matuesz Olbromski2, Ewa Nowak-Markwitz3, Marek Spaczynski3, Witold Kedzia4, Maciej Zabel5, Piotr Dziegiel6. 1. Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland bartosz.pula@umed.wroc.pl. 2. Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland. 3. Department of Gynecologic Oncology, University of Medical Sciences in Poznan, Poznan, Poland. 4. Department of Gynecology, University of Medical Sciences in Poznan, Poznan, Poland. 5. Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Histology and Embryology, University of Medical Sciences in Poznan, Poznan, Poland. 6. Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education in Wroclaw, Wroclaw, Poland.
Abstract
BACKGROUND: SOX18 is a transcription factor known to be involved in blood and lymphatic vessel, hair follicle development, and wound healing processes. In addition, it has been reported that SOX18 may influence cancer growth. The role of SOX18 expression in ovarian cancer (OC) has not been determined. MATERIALS AND METHODS: SOX18 expression was assessed in 85 OC cases using immunohistochemical methods and in ovarian cancer cell lines on the mRNA and protein level. RESULTS: SOX18 was expressed in cancer cell nuclei as well as the cytoplasm. Higher nuclear SOX18 expression was associated with presence of residual disease following surgical treatment (p=0.0158) and advanced disease stage (p=0.0056). Univariate survival analysis revealed that high SOX18 (p=0.0125) expression, presence of residual disease (p<0.0001) and advanced disease stage (p<0.0324) predicted poor patient outcome. CONCLUSION: SOX18 may be a new predictive marker for OC. Copyright
BACKGROUND:SOX18 is a transcription factor known to be involved in blood and lymphatic vessel, hair follicle development, and wound healing processes. In addition, it has been reported that SOX18 may influence cancer growth. The role of SOX18 expression in ovarian cancer (OC) has not been determined. MATERIALS AND METHODS:SOX18 expression was assessed in 85 OC cases using immunohistochemical methods and in ovarian cancer cell lines on the mRNA and protein level. RESULTS:SOX18 was expressed in cancer cell nuclei as well as the cytoplasm. Higher nuclear SOX18 expression was associated with presence of residual disease following surgical treatment (p=0.0158) and advanced disease stage (p=0.0056). Univariate survival analysis revealed that high SOX18 (p=0.0125) expression, presence of residual disease (p<0.0001) and advanced disease stage (p<0.0324) predicted poor patient outcome. CONCLUSION:SOX18 may be a new predictive marker for OC. Copyright